Your browser doesn't support javascript.
loading
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.
Connell, C M; Raby, S; Beh, I; Flint, T R; Williams, E H; Fearon, D T; Jodrell, D I; Janowitz, T.
Affiliation
  • Connell CM; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Raby S; Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK.
  • Beh I; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Flint TR; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Williams EH; Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK.
  • Fearon DT; Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK.
  • Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK.
  • Janowitz T; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Ann Oncol ; 28(7): 1678-1679, 2017 07 01.
Article in En | MEDLINE | ID: mdl-28430855
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Glucocorticoids / Immunosuppressive Agents / Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Glucocorticoids / Immunosuppressive Agents / Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article